Hypoxia-inducible factors and cancer

Clinical and Translational Oncology

Volumn 9, Issue 5, 2007, Pages 278-289

  Calzada, M J ^a   Peso, L ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Angiogenesis; Cancer; HIF; Hypoxia; VHL

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OXYGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1; UNCLASSIFIED DRUG;

ANAEROBIC METABOLISM; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL HYPOXIA; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMAN; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; OXYGEN SENSING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS;

EID: 34848898470     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0055-y     Document Type: Review

References (150)

1. Yao KS, Xanthoudakis S, Curran T, O'Dwyer PJ (1994) Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol 14:5997-6003
2. Cockman ME, Lancaster DE, Stolze IP et al (2006) Posttranslational hydroxylation of ankyrin repeats in IêB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A 103:14767-14772
3. Cummins EP, Berra E, Comerford KM et al (2006) Prolyl hydroxylase-1 negatively regulates IêB kinase-beta, giving insight into hypoxia-induced NFeêB activity. Proc Natl Acad Sci U S A 103:18154-18159
4. Rupec RA, Baeuerle PA (1995) The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. Eur J Biochem 234:632-640
5. Bishop, T, Lau KW, Epstein ACR et al (2004) Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol 2:e289
6. Hu C-J, Iyer S, Sataur A et al (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2α in stem cells. Mol Cell Biol 26:3514-3526
7. Shen C, Nettleton D, Jiang M et al (2005) Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans. J Biol Chem 280:20580-20588
8. Wang V, Davis DA, Haque M et al (2005) Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res 65:3299-3306
9. Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 306:rE12
10. Maynard MA, Qi H, Chung J et al (2003) Multiple splice variants of the human HIF-3alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278:11032-11040
11. Makino Y, Cao R, Svensson K et al (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414:550-554
12. Makino Y, Kanopka A, Wilson WJ et al (2002) Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 277:32405-32408
13. Lando D, Gorman JJ, White MF, Peet DJ (2003) Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Immunol 270:781-790
14. Ivan M, Kondo K, Yang H et al (2001) HIFalpha targeted for VHL-mediated destruction by pro-line hydroxylation: Implications for O2 sensing. Science 292:464-468
15. Jaakkola P, Mole DR, Tian YM et al (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472
16. Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340
17. Epstein AC, Gleadle JM, McNeill LA et al (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54
18. Koivunen P, Hirsila M, Kivirikko KI, Myllyharju J (2006) The length of peptide substrates has a marked effect on hydroxylation by the HIF prolyl 4-hydroxylases. J Biol Chem 281:28712-28720
19. Ehrismann D, Flashman E, Genn DN et al (2007) Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J 401:227-234
20. Taylor MS (2001) Characterization and comparative analysis of the EGLN gene family. Gene 275:125-132
21. Landazuri MO, Vara-Vega A, Viton M et al (2006) Analysis of HIF-prolyl hydroxylases binding to substrates. Biochem Biophys Res Commun 351:313-320
22. Willam C, Maxwell PH, Nichols L et al (2006) HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 41:68-77
23. Appelhoff RJ, Tian Y-M, Raval RR et al (2004) Differential function of the prolyl hydroxylases PHD1, PHD2 and PHD3 in the regulation of the hypoxia inducible factor. J Biol Chem 279:38458-38465
24. Berra E, Benizri E, Ginouves A et al (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1a in normoxia. EMBO J 22:4082-4090
25. Takeda K, Ho VC, Takeda H et al (2006) Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 26:8336-8346
26. del Peso L, Castellanos MC, Temes E et al (2003) The von Hippel Lindau/ hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 278:48690-48695
27. Marxsen JH, Stengel P, Doege K et al (2004) Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-a-prolyl-4-hydroxylases. Biochem J 381:761-767
28. Metzen E, Stiehl DP, Doege K et al (2005) Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: Identification of a functional hypoxia-responsive element. Biochem J 387:711-717
29. Pescador N, Cuevas Y, Naranjo S et al (2005) Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J 390:189-197
30. Berra E, Richard DE, Gothie E, Pouyssegur J (2001) HIF-1-dependent transcriptional activity is requiered for oxygen-mediated HIF-1a degradation. FEBS Lett 491:85-90
31. D'Angelo G, Duplan E, Boyer N et al (2003) Hypoxia up-regulates prolyl hydroxylase activity: A feedback mechansim that limits HIF-1 responses during reoxygenation. J Biol Chem 278:38183-38187
32. Lando D, Peet DJ, Whelan DA et al (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861
33. Lando D, Peet DJ, Gorman JJ et al (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466-1471
34. Hewitson KS, McNeill LA, Riordan MV et al (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277:26351-26355
35. Bilton R, Trottier E, Pouyssegur J, Brahimi-Horn MC (2006) ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol 16:616-621
36. Flugel D, Gorlach A, Michiels C, Kietzmann T (2007) Glycogen synthase kinase-3 phosphorylates hypoxia-inducible factor-1 alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 27:3253-3265
37. Mylonis I, Chachami G, Samiotaki M et al (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α. J Biol Chem 281:33095-33106
38. Goldberg MA, Dunning SP, Bunn HF (1988) Regulation of the erythropoietin gene: Evidence that the oxygen sensor is a heme protein. Science 242:1412-1415
39. Kaelin JWG (2005) ROS: Really involved in oxygen sensing. Cell Metab 1:357-358
40. Aragones J, Jones DR, Martin S et al (2001) Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension. J Biol Chem 276:10548-10555
41. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443
42. Jung Y-J, Isaacs JS, Lee S et al (2003) IL-1β mediated up-regulation of HIF-1α via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17:2115-2117
43. Laughner E, Taghavi P, Chiles K et al (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor-1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004
44. Pore N, Jiang Z, Shu H-K et al (2006) Akt1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4:471-479
45. αlvarez-Tejado M, Alfranca A, Aragones J et al (2002) Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia inducible factors by low oxygen tension. J Biol Chem 28:13508-13517
46. Arsham AM, Plas DR, Thompson CB, Simon MC (2002) Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277:15162-15170
47. Kaelin WG Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-682
48. Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
49. Maher ER, Kaelin WG Jr (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76:381-391
50. Esteban MA, Harten SK, Tran MG, Maxwell PH (2006) Formation of primary cilia in the renal epithelium is regulated by the von hippel-lindau tumor suppressor protein. J Am Soc Nephrol 17:1801-1806
51. Esteban MA, Tran MG, Harten SK et al (2006) Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66:3567-3575
52. Evans AJ, Russell RC, Roche O et al (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27:157-169
53. Krishnamachary B, Zagzag D, Nagasawa H et al (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66:2725-2731
54. Erler JT, Bennewith KL, Nicolau M et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226
55. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D et al (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 24:3446-3458
56. Calzada MJ, Esteban MA, Feijoo-Cuaresma M et al (2006) von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res 66:1553-1560
57. Hsu T, Adereth Y, Kose N, Dammai V (2006) Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem 281:12069-12080
58. Kamada M, Suzuki K, Kato Y et al (2001) von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res 61:4184-4189
59. Koochekpour S, Jeffers M, Wang PH et al (1999) The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19:5902-5912
60. Bluyssen HA, Lolkema MP, van Beest M et al (2004) Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 556:137-142
61. Hergovich A, Lisztwan J, Barry R et al (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5:64-70
62. Bindra RS, Vasselli JR, Stearman R et al (2002) VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62:3014-3019
63. Kim, M, Yan Y, Lee K et al (2004) Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. Biochem Biophys Res Commun 320:945-950
64. Davidowitz EJ, Schoenfeld AR, Burk RD (2001) VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 21:865-874
65. Esteban-Barragan MA, Avila P, Alvarez-Tejado M et al (2002) Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 62:29229-29236
66. Lewis MD, Roberts BJ (2003) Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein. Oncogene 22:3992-3997
67. Roe JS, Kim H, Lee SM et al (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22:395-405
68. Iturrioz X, Durgan J, Calleja V et al (2006) The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta. Biochem J 397:109-120
69. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D (1997) The von Hippel-Lindau gene product inhibits vascular permeability factor/ vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272:27509-27512
70. Okuda H, Saitoh K, Hirai S et al (2001) The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 276:43611-43617
71. Clifford SC, Cockman ME, Smallwood AC et al (2001) Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038
72. Hoffman MA, Ohh M, Yang H et al (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027
73. Ohh M, Yauch RL, Lonergan KM et al (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959-968
74. Kurban G, Hudon V, Duplan E et al (2006) Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66:1313-1319
75. Tang N, Mack F, Haase VH et al (2006) pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 26:2519-2530
76. Gnarra JR, Ward JM, Porter FD et al (1997) Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 94:9102-9107
77. Rankin EB, Higgins DF, Walisser JA et al (2005) Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25:3163-3172
78. Rankin EB, Tomaszewski JE, Haase VH (2006) Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66:2576-2583
79. Rathmell WK, Hickey MM, Bezman NA et al (2004) In vitro and in vivo models analyzing von Hippel-Lindau disease-specif ic mutations. Cancer Res 64:8595-8603
80. Zundel W, Schindler C, Haas-Kogan D et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396
81. Phillips RJ, Mestas J, Gharaee-Kermani M et al (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280:22473-22481
82. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545
83. αlvarez-Tejado M, Naranjo-Suarez S, Jimenez C et al (2001) Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: Protective role in apoptosis. J Biol Chem 276:22368-22374
84. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ (2000) Molecular genetic advances in tuberous sclerosis. Hum Genet 107:97-114
85. Brugarolas JB, Vazquez F, Reddy A et al (2003) TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell 4:147-158
86. Brugarolas J, Lei K, Hurley RL et al (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893-2904
87. Kaper F, Dornhoefer N, Giaccia AJ (2006) Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 66:1561-1569
88. Bernardi R, Guernah I, Jin D et al (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442:779-785
89. von Arnim AG, Chamovitz DA (2003) Protein homeostasis: A degrading role for Int6/eIF3e. Curr Biol 13:R323-325
90. Chen L, Uchida K, Endler A, Shibasaki F (2007) Mammalian tumor suppressor Int6 specifically targets HIF-2alpha for degradation by hypoxiaand pVHL-independent regulation. J Biol Chem 282:12707-12716
91. Schmid T, Zhou J, Kohl R, Brune B (2004) p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem J 380:289-295
92. Sanchez-Puig N, Veprintsev DB, Fersht AR (2005) Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell 17:11-21
93. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447
94. Ema M, Taya S, Yokotani N et al (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 94:4273-4278
95. Tian H, McKnight SL, Russell DW (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11:72-82
96. Wiesener MS, Jurgensen JS, Rosenberger C et al (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17:271-273
97. Carmeliet P, Dor Y, Herbert JM et al (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [published erratum appears in Nature 1998; 395:525]. Nature 394:485-490
98. Iyer NV, Leung SW, Semenza GL (1998) The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics 52:159-165
99. Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005-3015
100. Compernolle V, Brusselmans K, Acker T et al (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702-710
101. Peng J, Zhang L, Drysdale L, Fong GH (2000) The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci U S A 97:8386-8391
102. Scortegagna M, Ding K, Oktay Y et al (2003) Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/-mice. Nat Genet 35:331-340
103. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:E83
104. Raval RR, Lau KW, Tran MG et al (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675-5686
105. Covello KL, Simon MC, Keith B (2005) Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 65:2277-2286
106. Covello KL, Kehler J, Yu H et al (2006) HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20:557-570
107. Gordan JD, Bertout JA, Hu CJ et al (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 11:335-347
108. Acker T, Diez-Juan A, Aragones J et al (2005) Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 8:131-141
109. Giatromanolaki A, Koukourakis MI, Sivridis E et al (2001) Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85:881-890
110. Yoshimura H, Dhar DK, Kohno H et al (2004) Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: Correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10:8554-8560
111. Holmquist-Mengelbier L, Fredlund E, Lofstedt T et al (2006) Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10:413-423
112. Sivridis E, Giatromanolaki A, Gatter KC et al (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-1063
113. Sun X, Liu M, Wei Y et al (2006) Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas Cancer Gene Ther 13:428-435
114. Bracken C.P, Fedele AO, Linke S et al (2006) Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. J Biol Chem 281:22575-22585
115. Carroll VA, Ashcroft M (2006) Role of hypoxiainducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Res 66:6264-6270
116. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653-660
117. Adelman DM, Gertsenstein M, Nagy A et al (2000) Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses [In Process Citation]. Genes Dev 14:3191-3203
118. Maltepe E, Schmidt JV, Baunoch D et al (1997) Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403-407
119. Licht AH, Muller-Holtkamp F, Flamme I, Breier G (2006) Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood 107:584-590
120. Manalo DJ, Rowan A, Lavoie T et al (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-669
121. Tang N, Wang L, Esko J et al (2004) Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6:485-495
122. Forsythe JA, Jiang BH, Iyer NV et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613
123. Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J Biol Chem 272:23659-23667
124. Duan LJ, Zhang-Benoit Y, Fong GH (2005) Endothelium-intrinsic requirement for Hif-2alpha during vascular development. Circulation 111:2227-2232
125. Elvert G, Kappel A, Heidenreich R et al (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278:7520-7530
126. Kappel A, Ronicke V, Damert A et al (1999) Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 93:4284-4292
127. Takeda N, Maemura K, Imai Y et al (2004) Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 95:146-153
128. Calvani M, Rapisarda A, Uranchimeg B et al (2006) Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107:2705-2712
129. Phelan MW, Forman LW, Perrine SP, Faller DV (1998) Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med 132:519-529
130. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
131. Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425-434
132. Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem 281:9030-9037
133. Kim J-W, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 3:177-185
134. Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 3:187-197
135. Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601
136. Pollard PJ, Briere JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1{alpha} in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
137. Bensaad K, Tsuruta A, Selak MA et al (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107-120
138. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9:677-684
139. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598-608
140. To KK, Koshiji M, Hammer S, Huang LE (2005) Genetic instability: The dark side of the hypoxic response. Cell Cycle 4:881-882
141. Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 3:647-654
142. Kung AL, Zabludoff SD, France DS et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6:33-43
143. Mizuno T, Nagao M, Yamada Y et al (2005) Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 13:131-140
144. Nagasawa H, Uto Y, Kirk KL, Hori H (2006) Hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull 29:2335-2342
145. Burke B, Tang N, Corke KP et al (2002) Expression of HIF-1α by human macrophages: Implications for the use of macrophages in hypoxiaregulated cancer gene therapy. J Pathol 196:204-212
146. Liu S-C, Minton NP, Giaccia AJ, Brown JM (2002) Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 9:291-296
147. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF (2002) New oncolytic adenovirus with hypoxia-and estrogen receptor-regulated replication. Hum Gene Ther 13:1737-1750
148. Cuevas Y, Hernandez-Alcoceba R, Aragones J et al (2003) Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 63:6877-6884
149. Post DE, Van Meir EG (2003) A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22:2065-2072
150. Garber K (2006) Energy deregulation: Licensing tumors to grow. Science 312:1158-1159